Holen Sie sich die Stockscreener-App
1.03
1.94%
-0.00
Schlusskurs vom Vortag:
$1.03
Offen:
$1.07
24-Stunden-Volumen:
22,756
Relative Volume:
0.06
Marktkapitalisierung:
$3.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.60M
KGV:
-0.3259
EPS:
-3.16
Netto-Cashflow:
$-8.96M
1W Leistung:
+5.89%
1M Leistung:
+4.01%
6M Leistung:
-13.68%
1J Leistung:
-24.63%
1-Tages-Spanne:
$1.00
$1.1222
1-Wochen-Bereich:
$0.90
$1.16
52-Wochen-Spanne:
$0.8196
$1.5899
Artelo Biosciences Inc Stock (ARTL) Company Profile
Firmenname
Artelo Biosciences Inc
Sektor
Branche
Telefon
858-925-7049
Adresse
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Vergleichen Sie ARTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.02 | 3.13M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.11 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.89 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
613.06 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.50 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
245.08 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-12 | Eingeleitet | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times
New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan
Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times
ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView
Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Artelo Biosciences reports promising nonclinical CBD study - MSN
Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World
Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire
Revolutionary CBD Tablet Formulation Achieves Breakthrough Pharmacokinetic Results vs Epidiolex - StockTitan
Artelo Biosciences to Present its New Data on ART12.11 - GlobeNewswire
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - The Manila Times
Artelo's CBD Innovation Matches Epidiolex PerformanceGroundbreaking Study Revealed - StockTitan
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium - Marketscreener.com
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Drops By 42.2% - Defense World
Drug Designed to Treat Neuropathy Advances in Clinical Trials - Stony Brook University
Artelo Biosciences (NASDAQ:ARTL) Earns Buy Rating from D. Boral Capital - Defense World
Aemetis, Inc. (NASDAQ:AMTX) Holdings Trimmed by Jane Street Group LLC - Defense World
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - The Manila Times
Artelo Biosciences Completes First Phase 1 Cohort for Novel FABP5 Pain Treatment ART26.12 - StockTitan
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program - Benzinga
Artelo Biosciences Holds Annual Meeting; Directors Re-Elected and Independent Auditor Appointment Ratified - Defense World
Artelo Biosciences stock hits 52-week low at $0.97 By Investing.com - Investing.com Canada
Artelo Biosciences stock hits 52-week low at $0.97 - Investing.com
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Yahoo Finance
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - The Manila Times
Artelo's Cancer Drug Shows Breakthrough Results: 67% of Patients Reverse Weight Loss in Phase 1 Trial - StockTitan
Artelo Biosciences (ARTL) Stock Surges 5% Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences (ARTL) Shares Drop Amidst Biotech Sector Move - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
Finanzdaten der Artelo Biosciences Inc-Aktie (ARTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):